Deficient cotinine formation from nicotine is attributed to the whole deletion of the CΥP2A6 gene in humans

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 1, 2000, Pages 57-69

  Nakajima, Miki ^a   Yamagishi, Sho ichi ^b   Yamamoto, Hiroshi ^b   Yamamoto, Toshinori ^b   Kuroiwa, Yukio ^b   Yokoi, Tsuyoshi ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; CYTOCHROME P450 ISOENZYME; NICOTINE;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; DRUG METABOLISM; FEMALE; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

EID: 0033965729     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.103957     Document Type: Article

References (25)

1. 1. Benowitz NL, Jacob P III. Metabolism, pharmacokinetics, and pharmacodynamics of nicotine in man. In: Marton WR, VanLoon GR, Iwamoto ET, Davis L, editors. Tobacco smoking and nicotine: a neurobiological approach. New York: Plenum Press; 1987. p. 357-73.
2. 2. Kyerematen GA, Vesell ES. Metabolism of nicotine. Drug Metab Rev 1991;23:3-41.
3. 1′(5′) iminium ion. Biochem Biophys Res Commun 1979;91:991-6.
4. 4. Nakajima M, Yamamoto T, Nunoya KI, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996;24:1212-7.
5. 5. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone E, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994;343:62-3.
6. 6. Benowitz NL, Jacob P III, Sachs DPL. Deficient C-oxidation of nicotine. Clin Pharmacol Ther 1995;57:590-4.
7. 7. Fernandez-Salguero P, Gonzalez FJ. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 1995;5:S123-8.
8. 8. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-9.
9. 9. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995;57:651-60.
10. 10. Nunoya KI, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998;8:239-49.
11. 11. Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 1999;289:437-42.
12. 12. Nunoya KI, Yokoi T, Takahashi Y, Kimura K, Kinoshita M, Kamataki T. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem 1999;126:402-7.
13. 13. Finney DJ. Probit analysis. London: Cambridge University Press; 1964.
14. 14. Sambrook J, Fritsh EE, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989. p. 9.16-9.
15. 15. Umetsu Y, Yokoi T, Nunoya KI, Takahashi Y, Kinoshita M, Shimada T, et al. Improvement of genotyping method of CYP2A6 gene and allelic frequency in Japanese [abstract]. Abstracts of the 118th Meeting of the Pharmaceutical Society of Japan. Tokyo: Pharmaceutical Society of Japan; 1998;3:28.
16. 16. Oscarson M, Gullstén H, Rautio A, Bernal ML, Sinues B, Dahl ML, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998;438:201-5.
17. 17. Oscarson M, McLellan RA, Gullstén H, Yue QY, Lang MA, Bernal ML, et al. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999;448:105-10.
18. 18. Umetsu Y, Takahashi Y, Ariyoshi N, Kinoshita M, Nakura H, Tateishi T, et al. Genotyping method of the deletion allele of CYP2A6 gene in Japanese [abstract]. Xenobio Metab Dispos 1998;13:S193.
19. 19. Benowitz NL, Jacob P III, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics 1996;6:239-42.
20. 20. Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, Adlkofer F. Pharmacokinetics of nicotine, cotinine, and 3′-hydroxycotinine in cigarette smokers. Klin Wochenschr 1988;66:5-11.
21. 21. Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res 1998;45:517-24.
22. 22. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988;319: 1318-30.
23. 23. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998;393:750.
24. 24. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999;353:898-9.
25. 25. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrsoamine in human liver microsomes. Carcinogenesis 1992;13:1789-94.